Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck trims operations post-merger

This article was originally published in The Tan Sheet

Executive Summary

Merck plans to phase out operations at eight research and eight manufacturing sites as part of its goal to wring $3.5 billion in annual cost savings from its acquisition of Schering-Plough by 2012. In a July 8 release, Merck said the changes position the firm to "invest in key areas for future growth," including consumer care. The firm originally expected to cut about 15,000 jobs in the initial restructuring phase; it employed 100,000 as of December 2009. Merck expects the manufacturing and research cuts to save $2.7 billion to $3.1 billion by 2012. The $3.5 billion goal aligns with expectations provided in March 2009 when the firms announced the merger. The merger made Merck a competitor in the consumer products market with Schering OTC brands including MiraLAX laxative, Coppertone skin care, Afrin decongestant, Claritin allergy relief and Dr. Scholl's foot care products (1"The Tan Sheet" Feb. 22, 2010)
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS104293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel